As per the terms of the partnership, Martindale Pharma will take charge of commercial activities relating to Proveblue in the UK and Ireland.
The commercial terms of the agreement have not been disclosed.
According to the company, Proveblue is beneficial as it includes a new indication for chemical products-induced methaemoglobinaemia, and acute symptomatic treatment of medicinal methaemoglobinaemia besides the indication to treat children, adolescents and adults.
Provepharm CEO and founder Michel Feraud said Martindale has a good understanding of their market in the UK and Ireland and their shift to Proveblue would help enhance quality for patients.